

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28437 A1

(51) International Patent Classification⁷: **A61K 47/48**

(21) International Application Number: PCT/EP01/11427

(22) International Filing Date: 3 October 2001 (03.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00121744.7 5 October 2000 (05.10.2000) EP

(71) Applicant (*for all designated States except US*): **ARES TRADING S.A.** [CH/CH]; Château de Vaumarcus, CH-2028 Vaumarcus (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PIQUET, Gilles** [IT/IT]; Corso Nigra No 60, I-10010 Ivrea (IT). **BARBERO, Luca** [IT/IT]; V. Dei Cappuccini 6/A, I-10034 Chivasso (TO) (IT). **TRAVERSA, Silvio** [IT/IT]; Regione Mulini 74, I-10010 Palazzo Canavese (TO) (IT). **GATTI, Monica** [IT/IT]; Via Vittorio Nassano 18, I-27058 Voghera (PV) (IT).

(74) Agent: **SERONO INTERNATIONAL S.A.**; Intellectual Property, 12, chemin des Aulx, CH-1228 Plan-les-Ouates (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REGIOSELECTIVE LIQUID PHASE PEGYLATION

(57) Abstract: A method is described for a method for the regioselective liquid-phase pegylation of GRF, which increases the yield of the GRF-PEG conjugate having 1 PEG molecule covalently bound to the ε-amino group of Lys¹². This method is characterized in that the reaction is carried out in a structuring solvent, such as trifluorethanol.



WO 02/28437 A1

REGIOSELECTIVE LIQUID PHASE PEGYLATION

FIELD OF THE INVENTION

The present invention relates to a method for the regioselective liquid-phase
5 pegylation of GRF, which increases the yield of the GRF-PEG conjugate having 1 PEG
molecule covalently bound to the ϵ -amino group of Lys¹². This method is characterized
in that the reaction is carried out in a structuring solvent, as for example trifluorethanol.

BACKGROUND OF THE INVENTION

10 In the early 1980's several groups isolated and characterized growth hormone
releasing factor (GRF).

GRF (also called Somatorelin) is a peptide secreted by the hypothalamus, which
acts on its receptor and can promote the release of growth hormone (GH) from the
anterior pituitary. It exists as 44-, 40-, or 37-amino acid peptide; the 44-amino acid form
15 may be converted physiologically into shorter forms. All three forms are reported to be
active, the activity residing mainly in the first 29 amino acid residues. A synthetic
peptide corresponding to the 1-29 amino acid sequence of human GRF [GRF(1-29)],
also called Sermorelin, has been prepared by recombinant DNA technology as
described in European Patent EP 105 759.

20 Sermorelin has been used in the form of acetate for the diagnosis and treatment
of growth hormone deficiency.

GRF has indeed a therapeutic value for the treatment of certain growth hormone
related disorders. The use of GRF to stimulate the release of GH is a physiological
method in promoting long bone growth or protein anabolism.

25 One problem associated with the use of GRF relates to its short biological
half-life (about 12 to 30 minutes). The GRF(1-29)-NH₂ is subject to enzymatic
degradation and is rapidly degraded in the plasma *via* dipeptidylpeptidase IV (DPP-IV)
cleavage between residues Ala² and Asp³.

It is therefore advantageous to develop biologically stable, long acting GRF
30 analogues using specific chemical modification of GRF, in order to prevent or slow
down enzymatic degradation.

-2-

Polyethylene glycol (PEG) is a hydrophilic, biocompatible and non-toxic polymer of general formula $\text{H}(\text{OCH}_2\text{CH}_2)_n\text{OH}$, wherein $n \geq 4$. Its molecular weight could vary from 200 to 20,000 Dalton.

It has been demonstrated that the chemical conjugation of PEG in its monomethoxylated form to proteins and/or peptides significantly increases their duration of biological action. Like carbohydrate moieties in a glycoprotein, PEG provides a protective coating and increases the size of the molecule, thus reducing its metabolic degradation and its renal clearance rate.

PEG conjugation is an already established methodology for peptide and protein delivery pioneered by the fundamental studies of Davis and Abuchowski (Abuchowski et al., 1977a and 1977b). PEG conjugation to peptides or proteins generally resulted in non-specific chemical attachment of PEG to more than one amino acid residue. One of the key issues with this technology is therefore finding appropriate chemical methods to covalently conjugate PEG molecule(s) to specific amino acid residues.

Various PEG-protein conjugates were found to be protected from proteolysis and/or to have a reduced immunogenicity (Monfardini et al., 1995; and Yamsuki et al., 1988).

One approach was recently proposed for the site-specific conjugation of PEG to low molecular weight peptides, such as GRF, which was prepared by solid-phase peptide synthesis. In these conjugates a pegylated amino acid, prepared in advance, was introduced into the peptide sequence during the solid-phase synthesis. This procedure, however, dramatically complicates product purification that is known to be the critical step in solid phase synthesis. The presence of PEG, for its high molecular weight and its polydispersivity, is likely to yield final products with unacceptable impurities and/or products with missing amino acids, the latter being considered to occur commonly in the Merrifield procedure.

Mono-pegylation, meaning that only one PEG molecule is attached, using solid-phase synthesis to specific amino acid residues of $[\text{Ala}^{15}]\text{-GRF}(1\text{-}29)\text{-NH}_2$ has been recently reported in the literature (Felix et al., 1995). This study shows that $[\text{Ala}^{15}]\text{-GRF}(1\text{-}29)\text{-NH}_2$ pegylated at residues 21 or 25 retains the full *in-vitro* potency of the parent $[\text{Ala}^{15}]\text{-GRF}(1\text{-}29)\text{-NH}_2$. There is however no *in-vivo* data to show

-3-

whether these pegylated conjugates exhibit a longer duration of action with respect to the non-pegylated counterpart.

More recently, it has been demonstrated (Campbell et al., 1997) that the attachment of PEG with different molecular weights to the C-terminus of several analogs of GRF, again using solid-phase synthesis, had enhanced duration of action in both pig and mouse models as compared to the non-pegylated counterpart.

EP 400 472 and EP 473 084 disclose PEG derivatives obtained by using specific activated PEG derivatives. In the Examples also GRF is made to react with such activated PEG derivatives, however the specific GRF-PEG which are obtained according to such patent applications are not exactly identified nor in any way characterized. There is no mention of a specific PEG attachment site.

WO 99/27897 discloses a method for the site-specific preparation of GRF-PEG conjugates containing one or more than one PEG units (per GRF) covalently bound to Lys¹² and/or Lys²¹ and/or N^α, characterized in that the conjugation reaction between the GRF peptide and activated PEG is carried out in solution and the desired GRF-PEG conjugate is purified by chromatographic methods. According to such patent application the solvent was selected from the group consisting of a highly concentrated nicotinamide aqueous solution, a buffered aqueous solution of a defolding agent (such as urea) or a polar organic solvent selected among dimethyl sulfoxide, dimethyl formamide/buffer or acetonitrile/buffer. Dimethyl sulfoxide (DMSO) was mainly used in the Examples.

DESCRIPTION OF THE INVENTION

We have now found an improvement in the method already described in WO 99/27897, which consists in the use of a specific class of solvents, which will be herein defined as "structuring solvents". Such an improvement allows to orientate almost completely the mono-pegylation reaction towards the ε-amino group of Lys¹².

As a matter of fact, also selecting the correct molar ratio PEG/GRF, according to the present invention it is possible to obtain up to 85% of the GRF-PEG conjugate having 1 PEG molecule covalently bound to the ε-amino group of Lys¹² with respect to the total amount of mono-pegylated species. Other mono-pegylated species could have

-4-

been the GRF-PEG conjugate having 1 PEG molecule covalently bound to the ϵ -amino group of Lys²¹ the GRF-PEG conjugate conjugate having 1 PEG molecule covalently bound to the primary amino group in N ^{α} .

Therefore, the main embodiment of the present invention is method for the liquid-phase pegylation of GRF, which allows to obtain regioselectively GRF-PEG conjugate having 1 PEG molecule covalently bound to the ϵ -amino group Lys¹², characterized in that the reaction is carried out in a structuring solvent.

This and other advantages of the present process over those already described, in particular in WO 99/27897 can be listed as follows:

- a single monopegylated form of GRF, in large excess with respect to the other monopegylated form(s), can be reproducibly obtained when adequate reaction conditions are applied. Selectivity of the liquid-phase PEGylation of GRF procedure has been notably improved;
- a regioselective acylation reaction has been obtained without the use of protecting/deprotecting groups;
- higher reaction yields are consistently observed when an excess of activated PEG is reacted with GRF. Even a three fold excess of PEG (1PEG chain per primary amine group available) does not lead to the formation of more than 10% of the poorly active *in vitro* dipegylated GRF form. The major species remains the monopegylated form of GRF.

According to this invention the term "GRF", unless otherwise specified, is intended to cover any human GRF peptides, with particular reference to the 1-44, 1-40, 1-29 peptides and the corresponding amides thereof (containing an amide group at the N-terminus or C-terminus). The preferred GRF peptide is GRF(1-29)-NH₂.

"Structuring solvents" or "structure-promoting solvents" throughout the present invention is intended to refer to those solvents or co-solvents who are able to confer stability to the predominant conformation of a peptide or protein. Generally they are organic polar solvents, such as alcohols, and are known to be used as solvents or co-solvents of peptides or proteins for NMR (Nuclear Magnetic Resonance) or CD (Circular Dichroism) studies.

Among the alcohols trifluoethanol (TFE) is preferred according to the invention.

-5-

“N^α” throughout the present invention means the amino group at the N-terminal position of the peptide (Tyr).

The “activated PEG”(or “pegylating agent”) is any PEG derivative, which can be used as protein modifier, because it contains a functional group capable of reacting with some functional group in the protein/peptide to produce the PEG-protein/peptide conjugates. A review of PEG derivatives useful as protein modifiers can be found in Harris (1985). The activated PEG can be an alkylating reagent, such as PEG aldehyde, PEG epoxide or PEG tresylate, or it can be an acylating reagent, such as PEG ester.

The activated PEG is preferably used in its mono-methoxylated form. It has preferably a molecular weight between 2,000 and 20,000. Mono-methoxylated PEG_{5,000} is particularly preferred for the preparation of the activated PEG according to the present invention.

If activated PEG is an acylating agent, it preferably contains either a norleucine or ornithine residue bound to the PEG moiety *via* a carbamate linkage. These residues allow a precise determination of the linked PEG units per mole of peptide (see for example Sartore et al., 1991). Therefore, more in particular, the preferred activated PEG is mono-methoxylated PEG_{5,000} linked by means of a carbamate bond to the alpha amino group of norleucine, that is activated at the carboxy group as succinimidyl ester.

Another preferred activated PEG can be methoxy-PEG-succinimidyl propionate (“PEG-SPA”).

Branched PEGs are also in common use. The branched PEGs can be represented as R(-PEG-OH)_m in which R represents a central core moiety such as pentaerythritol or glycerol, and m represents the number of branching arms. The number of branching arms (m) can range from three to a hundred or more. The hydroxyl groups are subject to chemical modification.

Another branched form, such as that described in PCT patent application WO 96/21469, has a single terminus that is subject to chemical modification. This type of PEG can be represented as (CH₃O-PEG-)_pR-X, whereby p equals 2 or 3, R represents a central core such as lysine or glycerol, and X represents a functional group such as carboxyl that is subject to chemical activation. Yet another branched form, the “pendant

-6-

PEG”, has reactive groups, such as carboxyl, along the PEG backbone rather than at the end of PEG chains.

All these branched PEGs can be “activated” as indicated above.

“Pegylation” is the reaction by which a PEG-protein/peptide conjugate is
5 obtained starting from the activated PEG and the corresponding protein/peptide.

The molar ratio PEG:GRF can be 1:1, 2:1 or 3:1, but 3:1 is preferred according to the present invention.

The temperature is kept around the room temperature.

Even in this case, as for the process described in WO 99/27897, the pegylation
10 of the present invention increases the resistance to the proteolytic degradation, does not affect, or only slightly decreases, the biological activity, depending upon the extent of pegylation and allows to obtain products (the conjugates), which are more soluble in aqueous buffered solutions.

The present invention has been described with reference to the specific
15 embodiments, but the content of the description comprises all modifications and substitutions, which can be brought by a person skilled in the art without extending beyond the meaning and purpose of the claims.

The invention will now be described by means of the following Examples,
which should not be construed as in any way limiting the present invention. The
20 Examples will refer to the Figures specified here below.

DESCRIPTION OF THE FIGURES

Figure 1: it reports the semi-developed structure for the two activated PEGs, which have been used in the Examples.

25

EXAMPLES

Abbreviations

ACN	Acetonitrile
DMSO	Dimethylsulfoxide
30 GRF	Growth hormone releasing factor
HPLC	High Performance Liquid Chromatography

-7-

IEX	Ion-exchange
mPEG-Nle-Osu	Monomethoxypoly(ethylene glycol)-norleucine succinimidyl ester
RP	Reverse phase
5 TEA	Triethylamine
TFA	Trifluoroacetic acid
TFE	Trifluoroethanol (2,2,2-trifluoroethanol)

Preliminary NMR studies on GRF

10 GRF is a member of a family of peptides which are known to be characterised by a predominant α -helical secondary structure, especially in presence of solvents like methanol and trifluoroethanol in aqueous solutions (see Clore et al., 1986, and Theriault et al., 1988).

Further NMR studies were more recently done at LIMA (Bioindustry Park, Ivrea,
15 Turin, Italy). One of the main aim was to better elucidate the influence of solvents on the GRF structure, and to assess and eventual solvent-dependent conformational changes of lysine 12 and lysine 21 side-chains, changes which could modify the chemical reactivity of the amine groups.

These studies showed that GRF structure in DMSO was poorly structured and
20 highly fluxional.

On the other hand, in the methanol/water 75% mixture, the global folding of GRF consisted of two α -helix domains joined by a well-defined kink, which makes approximately a 90° angle between the axes of the α -helices.

In neat trifluoroethanol, NMR studies showed a secondary structure of GRF
25 basically α -helical at all temperature considered where the 2 α -helical tracts, are joined by a central flexible segment.

A major difference with the structure in MeOH/H₂O 75% mixture, is that this segment, joining the two α -helices, exists in multiple conformations and is highly dependent upon the temperature.

30 Further studies made at different temperatures with TFE showed that the second α -helix tract (fragment 18-28) is more stable than the first one (fragment 4-14).

-8-

The studies showed that TFE further enhances the α -helices stability already observed in methanol/water 75/25 mixture. This stabilisation appears to induce a conformational disorder in the part of the molecule (centred at fragment 16-19) joining them.

5 This structuring effect of TFE appears as a key element to the possible orientation of the PEGylation reaction.

This structuring effect of TFE clearly appears as a key element to the possible orientation of the PEGylation reaction.

Materials and reagents

10

Description	Lot n°
GRF ₁₋₂₉ (Bachem)	FGRF1299603
Methoxy-PEG-Nle-Osu (Shearwater Polymers)	PT-028-12
Methoxy-PEG-succinimidylpropionate (SPA), (Fluka)	85969
Trifluoroethanol (TFE), (Aldrich), spectrophotometric grade	

General method of synthesis

To GRF₁₋₂₉ bulk powder is added at once to trifluoroethanol. Dissolution rapidly occurs at room temperature under gentle agitation up to [GRF] = 20 mg/ml in
15 trifluoroethanol (TFE).

The chosen activated PEG reagent is then added under stirring at once as a dry powder, or in TFE solution, to reach final PEG:GRF molar ratios of 1:1, 2:1, or 3:1 (3:1 ratio is the preferred one).

The reaction mixture is then stirred at room temperature for a minimum of 6
20 hours. Trifluoroethanol is then evaporated under vacuum (30 °C water bath, 60 mTorr vacuum) and the reaction mixture stored at -80°C before purification.

Results

25 The quenched reaction mixture of GRF, monopegylated, and dipegylated species, is analyzed by reverse-phase HPLC and the respective yield of each species determined in percentage of area. The respective ratio of the two monopegylated

-9-

species at Lysine 12 and Lysine 21 is determined after purification of the crude material and in process analysis by reverse-phase HPLC.

Table 1 shows the results obtained at different molar ratio of PEG and GRF in DMSO and TFE.

5

TABLE 1

PEGylation of GRF reaction yields and ratio.

PEG:GRF Molar ratio	in DMSO				in TFE			
	1:1		1.5:1	2:1	1:1		2:1	3:1
Reaction time (h)	3	22	3	3	3	22	22	6
GRF unreacted (%*)	32	33	19	4	70	58	35	26
GRF-1PEG (%*)	48	48	51	20	25	37	53	65
GRF-2PEG (%*)	20	19	30	74	5	5	12	9
GRF-1PEG-Lys ¹² (% ^a)	50		47	48	96	96	96	96

%* means weight percentage in the final reaction product

10 %^a means weight percentage of GRF-1PEG-Lys¹² with respect to the total amount GRF-1PEG-Lys¹² + GRF-1PEG-Lys²¹.

"GRF-1PEG" refers to the total amount of mono-pegylated species

"GRF-2PEG" refers to the total amount of di-pegylated species

15 Comments to the results of Table 1

A maximum yield of 51% of GRF-1PEG-5K has been obtained in presence of DMSO, yield which dramatically decrease (from 51 to 20%) in a two-fold excess of PEG. On the contrary and quite unexpectedly, a **two-fold excess** of PEG versus GRF in presence of TFE **increases the yield of GRF-1PEG**. The same observation can be
20 made with a three-fold excess of PEG.

This example constitutes one of the main differences between the processes in DMSO and TFE. The reaction in TFE proceeds in a regioselective manner towards the quasi-exclusive formation of the pegylated GRF in position 12.

25 Table 2 indicates the ratio in % area obtained in RP-HPLC of the various species of the reaction mixture in two solvents, dimethylsulfoxide and trifluoroethanol, at various ratios, and with two different activated PEG with the same reactive succinimidyl ester (see Figure 1).

TABLE 2

Comparison yields and ratio of the various species obtained during PEGylation of GRF
in DMSO and TFE solution.

	in DMSO		In TFE				
	PEG-Nle	PEG-SPA	PEG-Nle	PEG-SPA	PEG-SPA	PEG-Nle	PEG-SPA
PEG:GRF Molar ratio	1:1	1:1	1:1	1.1	2:1	3:1	4:1
Reaction time (h)	3	3	24	24	24	24	24
GRF unreacted (%*)	32	31	53.9	51	34.6	26.2	5.5
GRF-1PEG (%*)	48	48.9	43.6	45	57	65	64
GRF-2PEG (%*)	18	16	2.5	3.3	8.6	8.6	30.1
GRF-1PEG-Lys ¹² (% ^b)	45	45	75	79	80	82.7	85

5 %* means weight percentage in the final reaction product

%^b means weight percentage of GRF-1PEG-Lys¹² with respect to the total amount
monopegylated GRF forms.

Comments to the results of Table 2

Comparable results are obtained with either activated PEG. The reaction in
absence of TEA, proceed with a different selectivity in TFE. In presence of a three to 4-
fold excess of PEG, 50 % of GRF-1PEG-Lys¹² species is formed, twice as much as the
15 maximum amount obtained in DMSO. The results obtained with a PEG:GRF ratio are
the best results obtained under the conditions tested.

Conclusions

20 PEGylation of GRF process in TFE lead to the formation of a major species, the
GRF-1PEG-Lys¹². The use of TFE as solvent reaction was showed to increase the
selectivity of the pegylation. TEA as nucleophilic enhancer orientates the positioning of
the PEG chains onto the GRF peptide.

Supported by the structuring effect of TFE on GRF₁₋₂₉ amide (NMR data),
possible advantages of this process over the process in DMSO are numerous and can be
25 summarized as follow:

- a regioselective acylation reaction has been obtained without the use of
protecting/deprotecting groups;

-11-

- higher yields of monopegylated GRF were experimentally obtained in presence of TFE, with respect to the reaction in DMSO;
- a large scale production of the monopegylated form of GRF will benefit of the advantages described within this protocol.

References

- Abuchowski A. et al., *J. Biol. Chem.*, **252**, 3571-3581, 1977a;
Abuchowski A. et al., *J. Biol. Chem.*, **252**, 3582-3586, 1977b;
5 Campbell R. et al. *J. Peptide Res.*, **49**, 527-537, 1997;
Clore G.M. et al., *J. Mol. Biol.*, **191**, 553-561 (1986).
Felix A.M. et al., *Int. J. Peptide Protein Res.*, **46**, 253-264, 1995;
Harris J.M., *Rev. Macromol. Chem. Phys.*, **C25**, pp. 325-76, 1985;
Monfardini et al., *Biocon. Chem.*, **6**, 62-69, 1995;
10 Sartore L. et al., *Appl. Biochem. Biotechnol.*, **27**, 45, 1991;
Sartore L., et al., *Applied Biochem. Biotechnol.*, **31**, 213-22, 1991;
Theriault Y. et al., *Biopolymers*, **27**, 1897-1904, 1988;
Yamsuki et al., *Agric. Biol. Chem.*, **52**, 2185-2196, 1988;
Zalipsky S. et al., *Advanced Drug Delivery Reviews*, **16**, 157-182, 1995.

-13-

CLAIMS

1. A method for the liquid-phase regioselective synthesis of the GRF-PEG conjugate having one PEG unit covalently bound to the ϵ amino group of Lys¹², characterized
5 in that the conjugation reaction between the GRF peptide and the activated PEG is carried out in a structuring solvent.
2. The method of claim 1, wherein the GRF peptide is h-GRF(1-29)-NH₂.
- 10 3. The method according to anyone of the preceding claims, wherein the activated PEG is an alkylating or acylating PEG in its mono-methoxylated form.
4. The method according to any of the preceding claims, in which the structuring solvent is trifluoroethanol.
- 15 5. The method according to any of the preceding claims, in which the conjugation reaction is carried out at room temperature.

SEQUENCE LISTING

<110> ARES-TRADING S.A.

<120> REGIOSELECTIVE LIQUID-PHASE PEGYLATION

<130> EP/432/Z

<160> 1

<170> PatentIn version 3.0

<210> 1

<211> 29

<212> PRT

<213> Synthetic peptide

<400> 1

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg
20 25

1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/11427

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, BIOSIS, EPO-Internal, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 27897 A (CALICETI PAOLO ;SCHIAVON ODDONE (IT); VERONESE FRANCESCO MARIA (IT) 10 June 1999 (1999-06-10) cited in the application page 5, paragraph 6; claims 1-3,5,9 page 6, paragraph 4 - paragraph 5 --- -/--	1-5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

25 February 2002

Date of mailing of the international search report

05/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/11427

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; KLOOSTERMAN D A ET AL: "1H NMR analysis and in vitro bioactivity of Leu27-bGRF(1-29)NH2 and its D-Ala2 and des-(Tyr1-Ala2)-analogs." retrieved from STN Database accession no. 92273938 XP002163248 abstract & PEPTIDE RESEARCH, (1991 MAR-APR) 4 (2) 72-8.,</p>	1-5
Y	<p>----- FELIX A M ET AL: "PEGYLATED PEPTIDES IV. ENHANCED BIOLOGICAL ACTIVITY OF SITE-DIRECTED PEGYLATED GRF ANALOGS" INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH,DK,MUNKSGAARD, COPENHAGEN, vol. 46, no. 3/04, 1 September 1995 (1995-09-01), pages 253-264, XP000526320 ISSN: 0367-8377 page 258, column 1, paragraph 2; table 1 -----</p>	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

I. International Application No

PCT/EP 01/11427

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9927897	A	10-06-1999	
		EP 0922446 A1	16-06-1999
		AU 1563399 A	16-06-1999
		BG 104484 A	29-12-2000
		BR 9815159 A	10-10-2000
		CN 1280483 T	17-01-2001
		EE 200000319 A	15-08-2001
		WO 9927897 A1	10-06-1999
		EP 1037587 A1	27-09-2000
		HU 0100507 A2	28-08-2001
		JP 2001524505 T	04-12-2001
		NO 20002664 A	13-07-2000
		PL 341139 A1	26-03-2001
		SK 8242000 A3	18-01-2001
		TR 200001615 T2	21-12-2000
		ZA 9811068 A	28-06-1999